Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study

Haematologica

Volumn 90, Issue 9, 2005, Pages 1186-1191

  Aricò, Maurizio ^a   Conter, Valentino ^b   Valsecchi, Maria Grazia ^c   Rizzari, Carmelo ^b   Pinta Boccalatte, Marie France ^d   Barisone, Elena ^e   Messina, Chiara ^f   De Rossi, Giulio ^g   Lo Nigro, Luca ^h   Pession, Andrea ⁱ   Locatelli, Franco ^j   Micalizzi, Concetta ^k   Basso, Giuseppe ^f   Masera, Giuseppe ^b  

^a Ospedale dei Bambini G Di Cristina   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^e OIRM   (Italy)

^f Catt Oncoematologia Pediatrica   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^k G GASLINI INSTITUTE   (Italy)

more..

Author keywords

ALL; Childhood; DNA index; Treatment reduction

Indexed keywords

ANTHRACYCLINE; ASPARAGINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SECOND CANCER; SKULL IRRADIATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PREDNISONE; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 25444461125     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Conter V, Aricò M, Valsecchi MG, Basso G, Biondi A, Madon E, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 2000;14:2196-204.
2. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000;14:2205-22.
3. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14:2247-56.
4. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33.
5. Harms DO, Janka-Schaub GE. Cooperative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234-9.
6. Kamps WA, Veerman AJ, van Wering ER, van Weerden JF, Slater R, van der Does-van den Berg A. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 2000; 14:2240-6.
7. Olson DP, Taylor BJ, La M, Sather H, Reaman GH, Ivy SP. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 2005;46:681-91.
8. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, et al. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-94.
9. Conter V, Schrappe M, Aricò M, Reiter A, Rizzari C, Dordelmann M., et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. J Clin Oncol 1997;15:2786-91.
10. +) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92:2730-41.
11. Valsecchi MG, Masera G. A new challenge in clinical research in childhood ALL: the prospective meta-analysis strategy for intergroup collaboration. Ann Oncol 1996;7:1005-8.
12. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
13. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-50.
14. Bossi G, Lanzarini L, Laudisa ML, Klersy C, Raisaro A, Aricò M. Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines. Med Pediatr Oncol 2001;36:593-600.
15. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
16. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48.
17. Loning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95:2770-5.
18. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34-9.
19. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, et al. The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83). Klin Paediat 1987;199:151-60.
20. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000;14:2276-85.
21. Whitehead VM, Vuchich MJ, Cooley LD, Lauer SJ, Mahoney DH, Shuster JJ, et al. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leuemia: a Pediatric Oncology Group study. Leuk Lymphoma 1998;31:507-19.
22. Shuster JJ, Wacker P, Pullen J, Humbert J, Humbert J, Land VJ, Mahoney DH Jr, et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1998; 16:2854-63.
23. Pession A, Valsecchi MG, Masera G, et al, for the Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP); Dutch Childhood Oncology Group (DCOG); Hungarian Pediatric Hematology Oncology Group (HUNGARY). Randomized use of extended high-dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. Submitted.
24. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94:1209-17.
25. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1992;80:1316-23.
26. Jackson JF, Boyett J, Pullen J, Brock B, Patterson R, Land V, et al. Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. A Pediatric Oncology Group study. Cancer 1990; 66:1183-9.
27. Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1992; 10:606-13.
28. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-22.
30. Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana Ematologia ed Oncologia Pediatrica. J Clin Oncol 1995;13:2497-502.
31. Arico M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia 2005;19:1145-52.